Work

Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Year: 2008

Type: article

Source: Blood

DOI: 10.1182/blood.v112.11.3236.3236

Authors: Michael W.N. Deininger, Michael J. Mauro, Yousif Matloub, Ritwik Sinha, Lynn Ploughman, David Liu, Jerald Radich

Institutions: Oregon Health & Science University, Bristol-Myers Squibb (United States), Fred Hutch Cancer Center

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2551530299

FWCI: 0.763

Cites:

Cited by: 9

Related to: 10